Cardiovascular Research Technologies (CRT)

Thumbnail

TAVR linked to stronger valve performance than SAVR in new 5-year study

TAVR is associated with a significantly lower risk of bioprosthetic valve dysfunction than SAVR, according to new data presented at CRT 2025 and simultaneously published in JACC

Medtronic's Evolut FX TAVR valve, designed with 3 golden markers that improve alignment

Self-expanding TAVR valves still linked to superior durability in patients with small annuli after 2 years

Researchers presented new two-year data from the SMART trial at CRT 2025 in Washington, D.C. Overall, self-expanding TAVR valves continue to show superior valve performance compared to balloon-expandable valves, and clinical outcomes remain comparable.